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Figure. Intestinal microangiopathy
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screened to ensure the presence of these oligosaccharides.
Results: Ten children were treated with milk, 8 boys and 2
girls. Ages at transplant ranged from 6 to 40 months. Di-
agnoses included non-malignant hematopoietic disorders
(n¼8) and leukemia (n¼2). Three children had sibling do-
nors, 1 a matched aunt and 6 unrelated donors; all received
bone marrow grafts. Treated cases were compared with 4
young children transplanted in the same time period who
received standard nutrition under the supervision of the
BMT dietician. Milk was given to provide 40% of caloric needs
(as breast milk cannot provide all nutritional needs for
children older than 6 months), from day -3 through day +14
after transplant. Enteral human milk was well tolerated with
all children receiving all the milk planned for administration.
Microbiome analysis showed no differences between study
groups at the start of transplant. Signiﬁcant differences were
observed between milk treated and control patient micro-
biomes at day 10 after transplant, when, consistent with
microbiome changes previously reported with GVHD risk
(Jenq et al 2012), control patients had signiﬁcantly increased
facultative anaerobes Streptococcaceae and Actino-
mycetaceae compared to milk fed patients. Measurement of
sIL2r levels showed elevation of levels at day 14 in controls
compared with cases.
Conclusions: This preliminary study suggests a possible role
for human milk in modulation of the microbiome and
reduction of a pro-inﬂammatory environment and a ran-
domized study is now in progress. Synthetic human milk
oligosaccharides have the potential to extend this strategy to
adults, and are currently being tested in a mouse model of
GVHD.Mucosal hemorrhages 12 (80%) 11 (52.4%) 5 (36%) 0.057
Loss of glands 11 (73.3%) 8 (38%) 0 (0%) <0.0001
Intravascularschistocytes 10 (66.7%) 5 (23.8%) 3 (21.4%) 0.016
Intravascular
ﬁbrinoid debris
8 (53.3%) 2 (9.55%) 2 (14%) 0.008
Intravascularmicrothrombi 4 (26.6%) 0 (0%) 0 (0%) 0.010
Endothelial cell swelling 13 (86.6%) 13 (61.9%) 7 (50%) 0.086
Endothelial cell separation 8 (53.3%) 3 (14.3%) 1 (7%) 0.007
Total denudation
of mucosa
7 (46.7%) 3 (14.3%) 0 (0%) 0.005293
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Introduction: We showed that high risk transplant-associ-
ated thrombotic microangiopathy (TMA) can present with
multisystem involvement and has poor outcome after HSCT
with <20% 1-year survival (Jodele, Blood 2014). TMA may
involve intestinal vasculature and can present with bleeding
and ischemic colitis. There are no established pathologic
criteria for diagnosis of intestinal TMA (iTMA). The goal of
our study was to review available tissue specimens obtained
after HSCT in order to identify histologic features of iTMA.
Methods: Fifty consecutive HSCT patients who underwent
endoscopy for gastrointestinal symptoms were evaluated for
histopathologic signs of iTMA using 8 histologic criteria
described in literature: mucosal hemorrhages, loss of glands,
schistocytes, ﬁbrinoid debris in the vessel lumen, intravas-
cular microthrombi, endothelial cell swelling, endothelial
cell separation and total denudation of mucosa (Figure). The
reviewing pathologist was blinded to patients’ clinical
history. Histologic markers were listed as present or absent.
For patients having multiple evaluations after HSCT, the
ﬁrst diagnostic tissue sample was used for this study.
Patients were divided into 3 clinical groups based on the
presence or absence of systemic TMA and intestinal graft
versus host disease (iGVHD): TMA/iGVHD, no TMA/iGVHD,and noTMA/no iGVHD. Systemic TMA was diagnosed using
rigorous clinical and diagnostic criteria. Comparison among
the groups was done using Fisher exact test.
Results: Fifteen patients (30%) had a clinical diagnosis of
systemic TMA.Out of 35patientswithout TMA, 21had clinical
and histologic evidence of gut GVHD while 14 did not. Inci-
dence of stage 3-4 gut GVHD was similar in the TMA/iGVHd
andnoTMA/iGVHDgroups (79%vs 64%). All histologic signs of
iTMA except for mucosal hemorrhages and endothelial cell
swelling were signiﬁcantly more common in patients with
systemic TMA (p<0.05). Intravascular thrombi were exclu-
sively seen only in patients with systemic TMA (Table).
Conclusions: We identiﬁed histologic features of iTMA that
can be used to delineate vascular injury of the bowel in pa-
tients with TMA after HSCT. Recognition of these histological
signs in patients with gastrointestinal symptoms after HSCT
may guide clinical decisions.
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Clinicians commonly use inhaled ribavirin to treat HSCT re-
cipients with Respiratory Syncytial Virus (RSV); however,
limited data exist to support this therapy. We evaluated 349
consecutive patients transplanted between June, 2008 and
December, 2013. Eighteen (5.2%) pediatric and young adult
patients (6 months to 25 years of age) developed an RSV
infection. Fifteen (83%) patients presented with an upper
respiratory tract infection (URTI) identiﬁed a median of 151
(range3e621) days post-HSCTand3 (17%) presentedwith, or
progressed to, a lower respiratory tract infection (LRTI)
identiﬁed amedian of 33 (range 10e117) days post-HSCT. All
3 patients with LRTI had signiﬁcant co-infections while 2/3
were less than 1 year of age at the time RSV was identiﬁed.
Fifteen (83%, 13/15 with URTI and 2/3 with LRTI) were still
receiving immunosuppressants. All 18 patients were lym-
phopenic (median 280, range 0 e 2120). Eleven of 15 (73%)
patientswith URTI and all 3 patientswith LRTIwere receiving
routine intravenous immunoglobulin (IVIG) supplementation
every 1-2 weeks to maintain normal IGG levels after HSCT.
RSV-targeted treatment included an increase in frequency or
additional IVIG administration for 4/15 and 3/3 URTI and LRTI
patients, respectively. ThreeURTI patients and 2 LRTI patients
receiving IVIG were also given palivizumab. No patients
received inhaled ribavirin or died as a direct result of RSV
infection suggesting that ribavirin may not be an essential
component of RSV treatment in pediatric HSCT recipients.295
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Background: Initial studies by our group and others
demonstrated that myeloablative conditioning (MAC) fol-
lowed by UCBT (matched at 4-6/6 HLA loci) in children with
malignant and non-malignant diseases was safe and well
tolerated (Wagner/Cairo et al, Blood, 1996; Kurtzberg et al,
NEJM,1996). However, there is a low concentration of CD34+
hematopoietic progenitor cells (HPC) in banked CB (Cairo/
Kurtzberg et al, Transfusion, 2005), resulting in delayed he-
matopoietic reconstitution and 10-20% incidence of graft
failure resulting in increased transplant-related mortality
(TRM) (Cairo et al, Blood,1997; Satwani/Cairo et al,
BBMT,2013). More recently, Robin et al have demonstrated
human stem and progenitor cells were detected in placental
tissue (Robin et al, Cell Stem Cell, 2009). Celgene Cellular
Therapeutics (CCT) has developed a proprietary, sterile
closed perfusion process for the collection of Human
Placental Derived Stem Cells (HPDSC) from full term pla-
centas. HPDSC are rich in HPCs, HPC CFU forming capabilities,
low in HLA Class I and II expression and enhance in-vivo
engraftment when combined with UCBT in NOD-SCID ani-
mals (Mendez-Ferrer et al, Nature,2010).
Objectives: To determine the safety and feasibility of
administering unmatched HPDSC in conjunction with single
and double UCBTs following MAC or reduced-intensity con-
ditioning (RIC) in children and adults with malignant and
non-malignant diseases.
Methods: We developed a multicenter consortium (CCT-
HPDSC-UCBT-PI-001) to investigate this approach (Fig. 1A).
Patients with eligible malignant and non-malignant
diseases with a single CB donor product (4/6e6/6 HLA
match) and total nucleated cell dose (TNC) 5.0 x 107/kg
or double UCBT (4/6e6/6 HLA match) and combined TNC
5.0 x 107/kg are eligible. The experimental design is
depicted in Fig. 1B.
Results: Nine patients enrolled to date: six with high-risk
malignant conditions (relapsed or hypodiploid Precursor B
ALL, FLT3+ AML, T-cell ALL induction failure) and three with
non-malignant disorders (X-linked adrenoleukodystrophy,
chronic granulomatous disease, congenital amegakaryocytic
thrombocytopenia). Mean  SD CB CD34 (3.9  1.8x105/kg)
and HPDSC CD34 doses (0.3  0.15 x105/kg) (p¼0.00005)and CBT clinical trial and (B) the overall treatment plan.
